Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
87.5M
-
Shares change
-
+36M
-
Total reported value, excl. options
-
$217M
-
Value change
-
+$93.7M
-
Put/Call ratio
-
0.42
-
Number of buys
-
53
-
Number of sells
-
-37
-
Price
-
$2.48
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q4 2024
116 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q4 2024.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87.5M shares
of 108M outstanding shares and own 80.75% of the company stock.
Largest 10 shareholders include BML Capital Management, LLC (14.3M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (9.63M shares), Vivo Capital, LLC (8.89M shares), Rock Springs Capital Management LP (6.2M shares), RA CAPITAL MANAGEMENT, L.P. (4.67M shares), VANGUARD GROUP INC (4.33M shares), D. E. Shaw & Co., Inc. (3.29M shares), JANUS HENDERSON GROUP PLC (2.8M shares), MARSHALL WACE, LLP (2.63M shares), and Samsara BioCapital, LLC (2.39M shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.